⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10217 | 1.00 | — | — | |
| SCHEMBL685385 | 1.00 | — | — | |
| SCHEMBL3359569 | 1.00 | — | — | |
| Water SCHEMBL27587846 | 0.97 | CA12 (0.42) | — | |
| Ethane SCHEMBL7360363 | 0.97 | CA12 (0.42) | — | |
| Methane SCHEMBL3247537 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL31732955 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL27149835 | 0.97 | — | — | |
| SCHEMBL24086950 | 0.92 | — | — | |
| SCHEMBL15495008 | 0.92 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3109232-A1 | OPTICALLY ACTIVE FORM OF MEPENZOLATE, AND AMELIORATING AGENT FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE WHICH CONTAINS SAME AS ACTIVE INGREDIENT | LTT Bio-Pharma Co., Ltd. (JP) | 2016-12-28 | — | — | EP | claimed |
| US-20160368873-A1 | Optically Active Form of Mepenzolate, and Ameliorating Agent for Chronic Obstructive Pulmonary Disease Which Contains Same as Active Ingredient | LTT BIO-PHARMA CO., LTD. | 2016-12-22 | — | — | US | claimed |
| CN-105980358-A | Methylpiperazinoate optically active form and chronic obstructive pulmonary disease ameliorating agent containing the same as active ingredient | 日本株式会社LTT生物医药 | 2016-09-28 | — | — | CN | claimed |
| US-12630562-B2 | Piperidylurea compounds and methods of use thereof | ARCUS BIOSCIENCES, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4142732-B1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260042777-A1 | PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-02-12 | — | — | US | disclosed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | disclosed |
| US-20250109122-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2025-04-03 | — | — | US | disclosed |
| US-12202817-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240158392-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2024-05-16 | — | — | US | disclosed |
| CN-111989321-B | KRAS G12C inhibitors | 米拉蒂治疗股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| WO-2009010299-A1 | SUBSTITUTED HETEROARYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009010299-A1 | SUBSTITUTED HETEROARYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2009-01-22 | — | — | WO | disclosed |
| EP-2009005-A1 | AZOLECARBOXAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
| CN-101163673-A | Novel muscarinic receptor antagonists | ASTRAZENECA AB (SE) | 2008-04-16 | — | — | CN | disclosed |
| US-20070287704-A1 | 7-amino-6-chloro-2-piperazin-1-yl-4-pyrrolidin-1-yl-pteridine; central nervous system, respiratory, gastrointestinal or inflammatory diseases; joints, skin or eyes diseases; cancer; phosphodiesterase 4 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-13 | — | — | US | disclosed |
| US-20070287704-A1 | 7-amino-6-chloro-2-piperazin-1-yl-4-pyrrolidin-1-yl-pteridine; central nervous system, respiratory, gastrointestinal or inflammatory diseases; joints, skin or eyes diseases; cancer; phosphodiesterase 4 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-13 | — | — | US | disclosed |
| US-20050101595-A1 | N-containing cycloalkyl-substituted amino-thiazole derivatives and pharmaceutical compositions for inhibiting cell proliferation and methods for their use | PFIZER INC. | 2005-05-12 | — | — | US | disclosed |
| WO-2005002577-A1 | DUAL NK1/NK3 ANTAGONISTS FOR TREATING SCHIZOPHRENIA | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-13 | — | — | WO | disclosed |
| US-5086051-A | 1H, 3H-pyrrolo[1,2-c]thiazole-7-carboxamide derivatives and pharmaceutical compositions containing them | RHONE-POULENC SANTE (FR) | 1992-02-04 | — | — | US | disclosed |